Evidence map›Paper›PMID 31277283›Full record

ArticleCancers2019

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma.

Xianqiong Liu, Junjie Hu, Xinhua Song, Kirsten Utpatel, Yi Zhang, Pan Wang, Xinjun Lu, Jie Zhang, Meng Xu, Tao Su and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Development of mutated β-catenin gene signature to identifyJHEP reports : innovation in hepatology · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Xianqiong LiuPharmacy Faculty, Hubei University of Chinese Medicine Wuhan, Wuhan 430065, China.
Junjie HuPharmacy Faculty, Hubei University of Chinese Medicine Wuhan, Wuhan 430065, China.
Xinhua SongDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA. xinhua.song@ucsf.edu.
Kirsten UtpatelInstitute of Pathology, University of Regensburg, Regensburg 93053, Germany.
Yi ZhangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Pan WangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Xinjun LuDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Jie ZhangDepartment of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
Meng XuDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Tao SuDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Li CheDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.
Jingxiao WangDepartment of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA 94143, USA.ORCID 0000-0002-7799-781X
Matthias EvertInstitute of Pathology, University of Regensburg, Regensburg 93053, Germany.
Diego F CalvisiInstitute of Pathology, University of Regensburg, Regensburg 93053, Germany.
Xin ChenPharmacy Faculty, Hubei University of Chinese Medicine Wuhan, Wuhan 430065, China. xin.chen@ucsf.edu.ORCID 0000-0002-9588-0164
University of California, San Francisco · USUniversity of Regensburg · DEHubei University of Chinese Medicine · CNChongqing University · CNPeking University · CNSun Yat-sen University · CN

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Y. Chen · 1986 to 2026
$30.7M
Foundation for the National Institutes of Health R01CA136606National Nature Science Founding of China No. 81602424National Nature Science Founding of China No. 81802774NIDDK NIH HHS P30 DK026743UCSF Liver Center P30DK026743
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

apoptosiscell proliferationhepatocellular carcinomaMEK inhibitorMLN0128pan-mTOR inhibitorPD901

Identifiers

PMID31277283
PMCPMC6679026
OpenAlexW2955141834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.